Polar Securities Has Cut Genesee & Wyo (GWR) Holding, Eleven Biotherapeutics (EBIO) Shorts Up By 0.74%

June 19, 2017 - By marketbeat

Polar Securities Inc decreased Genesee & Wyo Inc (GWR) stake by 25.85% reported in 2016Q4 SEC filing. Polar Securities Inc sold 53,425 shares as Genesee & Wyo Inc (GWR)’s stock declined 14.44%. The Polar Securities Inc holds 153,250 shares with $10.64 million value, down from 206,675 last quarter. Genesee & Wyo Inc now has $4.20 billion valuation. It is 0.00% or $0 reaching $67.17 per share. It is down 13.88% since June 19, 2016 and is uptrending. It has underperformed by 2.82% the S&P500.

Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) had an increase of 0.74% in short interest. EBIO’s SI was 1.70 million shares in June as released by FINRA. Its up 0.74% from 1.68 million shares previously. With 180,300 avg volume, 9 days are for Eleven Biotherapeutics Incorporated (NASDAQ:EBIO)’s short sellers to cover EBIO’s short positions. The SI to Eleven Biotherapeutics Incorporated’s float is 19.51%. About 57,746 shares traded. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 30.97% since June 19, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) has “Neutral” rating given on Wednesday, March 16 by Citigroup. Leerink Swann downgraded the shares of EBIO in report on Tuesday, January 19 to “Market Perform” rating. The firm earned “Neutral” rating on Tuesday, January 19 by Citigroup. The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) earned “Outperform” rating by Leerink Swann on Saturday, August 15.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $34.84 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 7.24 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

Investors sentiment decreased to 1 in 2016 Q4. Its down 1.29, from 2.29 in 2016Q3. It dropped, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported. Spark Management Limited Liability Corp invested in 140,500 shares or 0.02% of the stock. 100 were accumulated by Reilly Financial Advsr Llc. Oxford Asset holds 0.02% or 179,627 shares in its portfolio. Barclays Public Limited Co holds 13 shares. Geode Management Ltd reported 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Bancshares Of Ny Mellon reported 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Price T Rowe Assocs Md, Maryland-based fund reported 28,200 shares. Susquehanna Interest Grp Inc Limited Liability Partnership holds 0% or 15,586 shares. Blackrock Fund Advisors owns 2,365 shares for 0% of their portfolio. Credit Suisse Ag, Switzerland-based fund reported 14,860 shares. Blackrock Institutional Trust Na has 442,085 shares for 0% of their portfolio. Morgan Stanley stated it has 4,080 shares or 0% of all its holdings. Citigroup holds 500 shares or 0% of its portfolio. Royal Bankshares Of Canada reported 500 shares. Fiduciary Comm has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO).

Analysts await Genesee & Wyoming Inc (NYSE:GWR) to report earnings on August, 7. They expect $0.73 EPS, down 9.88% or $0.08 from last year’s $0.81 per share. GWR’s profit will be $45.65 million for 23.00 P/E if the $0.73 EPS becomes a reality. After $0.53 actual EPS reported by Genesee & Wyoming Inc for the previous quarter, Wall Street now forecasts 37.74% EPS growth.

Polar Securities Inc increased Gp Invts Acquisition Cor stake by 208,724 shares to 2.16M valued at $21.36M in 2016Q4. It also upped Verisign Inc (Prn) stake by 10.00M shares and now owns 50.00 million shares. Sprott Physical Silver Tr (PSLV) was raised too.

Among 10 analysts covering Genesee & Wyoming Inc. (NYSE:GWR), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Genesee & Wyoming Inc. had 26 analyst reports since August 5, 2015 according to SRatingsIntel. The company was downgraded on Friday, December 4 by Bank of America. RBC Capital Markets maintained Genesee & Wyoming Inc (NYSE:GWR) on Friday, April 29 with “Sector Perform” rating. The firm earned “Outperform” rating on Tuesday, August 4 by Cowen & Co. The firm has “Neutral” rating by Bank of America given on Friday, September 11. As per Monday, October 12, the company rating was maintained by Deutsche Bank. On Tuesday, February 23 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. Cowen & Co maintained it with “Outperform” rating and $77 target in Friday, October 21 report. Bank of America upgraded Genesee & Wyoming Inc (NYSE:GWR) on Wednesday, April 19 to “Buy” rating. The rating was maintained by Cowen & Co with “Outperform” on Wednesday, November 2. Bank of America upgraded Genesee & Wyoming Inc (NYSE:GWR) on Monday, February 22 to “Neutral” rating.

Investors sentiment increased to 1.89 in Q4 2016. Its up 0.72, from 1.17 in 2016Q3. It improved, as 14 investors sold GWR shares while 75 reduced holdings. 55 funds opened positions while 113 raised stakes. 58.36 million shares or 5.62% more from 55.25 million shares in 2016Q3 were reported. Commonwealth Of Pennsylvania School Empls Retrmt has 0.01% invested in Genesee & Wyoming Inc (NYSE:GWR) for 9,075 shares. Price T Rowe Associates Md accumulated 0.02% or 1.19 million shares. Walleye Trading Lc stated it has 0% of its portfolio in Genesee & Wyoming Inc (NYSE:GWR). Neuberger Berman Grp Inc holds 0.01% of its portfolio in Genesee & Wyoming Inc (NYSE:GWR) for 104,870 shares. Da Davidson And Com reported 1,129 shares or 0% of all its holdings. First Personal Fin Svcs reported 0.02% in Genesee & Wyoming Inc (NYSE:GWR). Btim accumulated 144,659 shares or 0.16% of the stock. The California-based Jacobs And Ca has invested 0.29% in Genesee & Wyoming Inc (NYSE:GWR). Texas Permanent School Fund accumulated 44,747 shares. South Dakota Council has 0.09% invested in Genesee & Wyoming Inc (NYSE:GWR). Credit Suisse Ag stated it has 52,051 shares. State Of New Jersey Common Pension Fund D holds 0.04% of its portfolio in Genesee & Wyoming Inc (NYSE:GWR) for 150,000 shares. Public Employees Retirement Association Of Colorado invested in 0.01% or 13,011 shares. Blackrock Institutional Na has 0.02% invested in Genesee & Wyoming Inc (NYSE:GWR) for 1.73 million shares. Vanguard Group Inc, Pennsylvania-based fund reported 4.59M shares.

Since February 14, 2017, it had 1 buying transaction, and 6 insider sales for $2.18 million activity. Liucci Christopher F sold 1,677 shares worth $108,133. $269,318 worth of stock was sold by Walsh Matthew O. on Friday, May 26. HELLMANN JOHN C sold $1.04 million worth of stock or 14,015 shares. $297,680 worth of stock was sold by FULLER MORTIMER B III on Tuesday, February 14. Fergus Allison M sold $176,897 worth of stock or 2,688 shares. Another trade for 6,071 shares valued at $390,851 was sold by Gallagher Timothy J. Another trade for 1,560 shares valued at $101,041 was bought by NEUPAVER ALBERT J.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: